Non-vitamin-K oral anticoagulants (NOACs) for the prevention of secondary stroke

@article{Diener2018NonvitaminKOA,
  title={Non-vitamin-K oral anticoagulants (NOACs) for the prevention of secondary stroke},
  author={H. Diener and G. Ntaios and M. O'Donnell and J. Easton},
  journal={Expert Opinion on Pharmacotherapy},
  year={2018},
  volume={19},
  pages={1597 - 1602}
}
ABSTRACT Introduction: In patients with atrial fibrillation (AF), oral anticoagulation with vitamin K antagonists (VKA) (warfarin, phenprocoumon) is effective both for primary and secondary stroke prevention with a 60–70% relative reduction in stroke risk compared with placebo. Mortality is reduced by 26%. VKA have a number of well-documented shortcomings which were overcome by non-vitamin-K oral anticoagulants (NOACs). Areas covered: Results of randomized trials for four NOACs (apixaban… Expand
8 Citations
Non-vitamin K oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation
  • 1
  • PDF
Anticoagulant Selection in Relation to SAMe-TT2R2 Score in Patients with Atrial Fibrillation: The GLORIA-AF Registry.
Stroke: Insights into Thromboembolism Treatment and Prevention through the Decades.
  • 1
  • PDF
Beginn der Antikoagulation nach akutem Schlaganfall

References

SHOWING 1-10 OF 43 REFERENCES
Novel oral anticoagulants in secondary prevention of stroke.
  • 11
Apixaban versus warfarin in patients with atrial fibrillation.
  • 4,610
  • PDF
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2.
  • 77
  • PDF
Apixaban in patients with atrial fibrillation.
  • 1,545
  • PDF
Dabigatran versus warfarin in patients with atrial fibrillation.
  • 6,479
  • PDF
...
1
2
3
4
5
...